Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial crawled time : 00:00 save search
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
Published: 2024-04-16 (Crawled : 00:00) - biospace.com/
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
tezspire copd
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-07 (Crawled : 00:00) - globenewswire.com
REPL | $6.33 -1.4% -1.58% 630K
|
Health Technology
|
| O: 3.27%
H: 0.13%
C: -4.17%
association presentation cancer cell research meeting skin trial results
LUXH FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages LuxUrban Hotels, Inc. Investors to Secure Counsel Before Important April 12 Deadline in Securities Class Action - LUXH
Published: 2024-04-02 (Crawled : 00:00) - prnewswire.com
LUXH | $0.95 9.2% 8.47% 330K
|
|
| O: -0.71%
H: 2.86%
C: -2.86%
BCDRF | $4.978 -8.71% 100
|
Finance
|
| O: 3.9%
H: 4.33%
C: 4.33%
SHLS | $8.49 0.36% 0.29% 2.8M
|
|
| O: 0.19%
H: 2.0%
C: 0.84%
SAN | $5.05 1.2% 0.59% 4.7M
|
Finance
|
| O: 1.04%
H: 1.23%
C: 0.82%
deadline trial
Translational Vision Science and Technology Journal Publishes RadiusXR's NOVA Clinical Trial, Demonstrating Industry-Leading Accuracy and Innovation in Visual Field Testing for Virtual Reality Perimetry
Published: 2024-03-25 (Crawled : 00:00) - biospace.com/
GKOS | $100.93 -0.17% 0.0% 520K
|
Health Technology
|
| O: 0.73%
H: 2.38%
C: 0.0%
innovation vision technology
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Published: 2024-03-22 (Crawled : 00:00) - globenewswire.com
HCM | $18.41 0.88% 0.84% 58K
|
Health Technology
|
| O: -4.4%
H: 0.97%
C: -0.73%
eslim-02 antibody anemia trial china
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
Published: 2024-03-19 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -1.51%
H: 0.0%
C: 0.0%
ibi302 macular trial
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
Published: 2024-02-26 (Crawled : 00:00) - biospace.com/
KZR | $0.8014 -2.98% -3.04% 450K
|
Health Technology
|
| O: 1.09%
H: 3.74%
C: -1.52%
lupus life approval sciences trial china
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
Published: 2024-02-11 (Crawled : 00:00) - prnewswire.com
ARCT 4 | $26.98 -3.4% -3.44% 270K
|
Health Technology
|
| O: 0.86%
H: 4.25%
C: 4.1%
csl112 trial results
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2024-02-04 (Crawled : 00:00) - globenewswire.com
PLRX | $11.9 -4.95% -5.39% 370K
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: -5.78%
liver positive fibrosis bexotegrast trial therapeutics
SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa
Published: 2024-01-24 (Crawled : 00:00) - biospace.com/
NTLA | $21.17 -1.67% -1.75% 710K
|
Health Technology
|
| O: 1.28%
H: 1.0%
C: -4.06%
spvn06 trial
Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients
Published: 2024-01-18 (Crawled : 00:00) - biospace.com/
HOTH | $1.17 -1.68% 1.2% 17K
|
Health Technology
|
| O: 5.43%
H: 13.24%
C: 0.74%
ht-001 fda approval treat trial therapeutics
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
Published: 2024-01-09 (Crawled : 00:00) - prnewswire.com
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: 0.65%
H: 0.69%
C: -0.73%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 0.0%
H: 0.53%
C: -2.19%
obesity first chinese key trial
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
Published: 2024-01-04 (Crawled : 00:00) - biospace.com/
GOVX | $1.54 1.27% 35K
|
Health Technology
|
| O: 4.19%
H: 0.0%
C: -6.41%
gedeptin cancer trial advanced
Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan
Published: 2024-01-04 (Crawled : 00:00) - biospace.com/
CYBN | $0.355 -0.85% 3.3M
|
n/a
|
| O: 0.65%
H: 3.49%
C: 3.49%
first fibromyalgia treatment trial therapeutics
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
Published: 2023-12-28 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: -1.32%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: 0.08%
H: 0.81%
C: -0.19%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.52%
H: 0.72%
C: -0.34%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 0.35%
H: 1.07%
C: -0.27%
candidate tumors collaboration trial advanced china therapy
Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes
Published: 2023-12-18 (Crawled : 00:00) - biospace.com/
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: 1.03%
H: 1.08%
C: 0.73%
breast cancer trials plus initiated
Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia
Published: 2023-12-14 (Crawled : 00:00) - biospace.com/
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
lancet publication schizophrenia trial therapeutics
HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
Published: 2023-12-13 (Crawled : 00:00) - globenewswire.com
HCM | $18.41 0.88% 0.84% 58K
|
Health Technology
|
| O: -2.54%
H: 3.89%
C: 3.41%
renal cell trial advanced china
Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS
Published: 2023-12-11 (Crawled : 00:00) - biospace.com/
GERN | $3.58 2.29% 1.96% 5.7M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.76%
transfusion durability risk
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
Published: 2023-12-11 (Crawled : 00:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.77%
H: 1.52%
C: 0.58%
yescarta t-cell response therapy
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.